Hims & Hers Health Free Cash Flow 2020-2025 | HIMS
Hims & Hers Health annual/quarterly free cash flow history and growth rate from 2020 to 2025. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Hims & Hers Health free cash flow for the quarter ending March 31, 2025 was 53.76, a year-over-year.
- Hims & Hers Health free cash flow for the twelve months ending March 31, 2025 was , a year-over-year.
- Hims & Hers Health annual free cash flow for 2024 was $0.209B, a 272.23% increase from 2023.
- Hims & Hers Health annual free cash flow for 2023 was $0.056B, a 292.39% decline from 2022.
- Hims & Hers Health annual free cash flow for 2022 was $-0.029B, a 17.02% decline from 2021.
| Hims & Hers Health Annual Free Cash Flow | |
|---|---|
| 2024 | 209.43 |
| 2023 | 56.26 |
| 2022 | -29.25 |
| 2021 | -35.24 |
| 2020 | -4.22 |
| 2019 | -75.18 |
| 2018 | 0.00 |
| Hims & Hers Health Quarterly Free Cash Flow | |
|---|---|
| 2025-03-31 | 53.76 |
| 2024-12-31 | 209.43 |
| 2024-09-30 | 147.56 |
| 2024-06-30 | 65.64 |
| 2024-03-31 | 15.26 |
| 2023-12-31 | 56.26 |
| 2023-09-30 | 42.91 |
| 2023-06-30 | 21.00 |
| 2023-03-31 | 8.85 |
| 2022-12-31 | -29.25 |
| 2022-09-30 | -21.13 |
| 2022-06-30 | -26.07 |
| 2022-03-31 | -19.50 |
| 2021-12-31 | -35.24 |
| 2021-09-30 | -31.59 |
| 2021-06-30 | -15.47 |
| 2021-03-31 | -16.01 |
| 2020-12-31 | -4.22 |
| 2020-09-30 | -3.50 |
| 2020-06-30 | -6.15 |
| 2020-03-31 | -5.46 |
| 2019-12-31 | |
| 2019-09-30 | -0.21 |
| 2019-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $12.904B | $1.477B |
| Hims & Hers Health Inc. is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling medical care for numerous conditions related to mental health, sexual health, dermatology, primary care and more. Hims & Hers Health Inc., formerly known as Oaktree Acquisition Corp., is based in San Francisco. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $47.457B | 60.38 |
| Doximity (DOCS) | United States | $11.414B | 52.84 |
| Tempus AI (TEM) | United States | $11.164B | 0.00 |
| IRhythm Technologies (IRTC) | United States | $4.284B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.801B | 59.38 |
| Hinge Health (HNGE) | United States | $3.571B | 0.00 |
| Privia Health (PRVA) | United States | $2.402B | 164.21 |
| 10x Genomics (TXG) | United States | $1.737B | 0.00 |
| Schrodinger (SDGR) | United States | $1.631B | 0.00 |
| Phreesia (PHR) | United States | $1.585B | 0.00 |
| Azenta (AZTA) | United States | $1.576B | 73.25 |
| Enovis (ENOV) | United States | $1.573B | 8.77 |
| Clover Health Investments (CLOV) | United States | $1.545B | 0.00 |
| Omnicell (OMCL) | United States | $1.324B | 23.36 |
| Evolent Health (EVH) | United States | $1.166B | 99.30 |
| Claritev (CTEV) | United States | $0.652B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.559B | 0.00 |
| Standard BioTools (LAB) | United States | $0.532B | 0.00 |
| Veradigm (MDRX) | United States | $0.503B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.487B | 0.00 |
| Talkspace (TALK) | United States | $0.421B | 125.75 |
| TruBridge (TBRG) | United States | $0.353B | 783.33 |
| Outset Medical (OM) | United States | $0.328B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.270B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.258B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.240B | 0.00 |
| CapsoVision (CV) | United States | $0.185B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.161B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.160B | 0.00 |
| American Well (AMWL) | United States | $0.140B | 0.00 |
| Pulmonx (LUNG) | United States | $0.134B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.118B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.118B | 0.00 |
| CareCloud (CCLD) | United States | $0.104B | 3.95 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.099B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.083B | 0.00 |
| 111 (YI) | China | $0.063B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.052B | 0.00 |
| HeartBeam (BEAT) | United States | $0.043B | 0.00 |
| Zhongchao (ZCMD) | China | $0.026B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.022B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.008B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| PROFUSA (PFSA) | United States | $0.004B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.000B | 0.00 |